Survival Analysis of Conversion Surgery in Borderline Resectable and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma Addressing Selection and Immortal Time Bias: A Retrospective Single-Center Study.
Borderline resectable
Immortal time bias
Pancreatic cancer
Pancreatic ductal adenocarcinoma
Selection bias
Unresectable locally advanced
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
03 Oct 2024
03 Oct 2024
Historique:
received:
23
05
2024
accepted:
03
09
2024
medline:
3
10
2024
pubmed:
3
10
2024
entrez:
3
10
2024
Statut:
aheadofprint
Résumé
The purpose of this study was to provide a detailed evaluation of the oncological advantages of surgery following neoadjuvant chemotherapy (NAC) for patients with borderline resectable (BR) or unresectable (UR) pancreatic ductal adenocarcinoma (PDAC), with a focus on minimizing biases. Recently, NAC has become the standard care for BR or UR locally advanced (UR-LA) PDAC, however, many studies have assessed survival benefits and favorable variables without consideration for biases, particularly immortal time bias. This study included patients diagnosed with BR or UR-LA PDAC at Juntendo University Hospital from 2019 to 2022. To mitigate bias, we applied methods such as propensity score matching (PSM), time-dependent covariate Cox proportional hazard regression analysis (TDC), landmark analysis, and multivariable Cox proportional hazards regression model. The study analyzed 124 patients, dividing them into a surgery group (n = 57) and a chemotherapy-only group (n = 67). After PSM, there were 21 matched pairs. Survival analysis using TDC analysis showed that the surgery group had significantly better overall survival compared with the chemotherapy-only group in both the entire cohort and the matched pairs. Cox regression analysis of the entire cohort also revealed a similar superiority of surgery, while the landmark analysis showed varying results depending on the landmark setting. After careful adjustment for selection and immortal time biases, surgery following NAC appears to significantly extend survival in patients with BR or UR PDAC.
Sections du résumé
BACKGROUND
BACKGROUND
The purpose of this study was to provide a detailed evaluation of the oncological advantages of surgery following neoadjuvant chemotherapy (NAC) for patients with borderline resectable (BR) or unresectable (UR) pancreatic ductal adenocarcinoma (PDAC), with a focus on minimizing biases. Recently, NAC has become the standard care for BR or UR locally advanced (UR-LA) PDAC, however, many studies have assessed survival benefits and favorable variables without consideration for biases, particularly immortal time bias.
PATIENTS AND METHODS
METHODS
This study included patients diagnosed with BR or UR-LA PDAC at Juntendo University Hospital from 2019 to 2022. To mitigate bias, we applied methods such as propensity score matching (PSM), time-dependent covariate Cox proportional hazard regression analysis (TDC), landmark analysis, and multivariable Cox proportional hazards regression model.
RESULTS
RESULTS
The study analyzed 124 patients, dividing them into a surgery group (n = 57) and a chemotherapy-only group (n = 67). After PSM, there were 21 matched pairs. Survival analysis using TDC analysis showed that the surgery group had significantly better overall survival compared with the chemotherapy-only group in both the entire cohort and the matched pairs. Cox regression analysis of the entire cohort also revealed a similar superiority of surgery, while the landmark analysis showed varying results depending on the landmark setting.
CONCLUSIONS
CONCLUSIONS
After careful adjustment for selection and immortal time biases, surgery following NAC appears to significantly extend survival in patients with BR or UR PDAC.
Identifiants
pubmed: 39361176
doi: 10.1245/s10434-024-16203-x
pii: 10.1245/s10434-024-16203-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Society of Surgical Oncology.
Références
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607–20.
doi: 10.1016/S0140-6736(10)62307-0
pubmed: 21620466
pmcid: 3062508
Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.
doi: 10.1056/NEJMoa1304369
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.
doi: 10.1056/NEJMoa1011923
pubmed: 21561347
Igarashi T, Yamada S, Hoshino Y, et al. Prognostic factors in conversion surgery following nab-paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: results of a dual-center study. Ann Gastroenterol Surg. 2023;7(1):157–66.
doi: 10.1002/ags3.12613
pubmed: 36643365
Ushida Y, Inoue Y, Oba A, et al. optimizing indications for conversion surgery based on analysis of 454 consecutive Japanese cases with unresectable pancreatic cancer who received modified FOLFIRINOX or gemcitabine plus nab-paclitaxel: a single-center retrospective study. Ann Surg Oncol. 2022;29(8):5038–50.
doi: 10.1245/s10434-022-11503-6
pubmed: 35294658
Truty MJ, Kendrick ML, Nagorney DM, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer. Ann Surg. 2021;273(2):341–9.
doi: 10.1097/SLA.0000000000003284
pubmed: 30946090
Rangelova E, Wefer A, Persson S, et al. Surgery improves survival after neoadjuvant therapy for borderline and locally advanced pancreatic cancer: a single institution experience. Ann Surg. 2021;273(3):579–86.
doi: 10.1097/SLA.0000000000003301
pubmed: 30946073
Natsume S, Shimizu Y, Senda Y, et al. Conversion surgery only for highly selected patients with unresectable pancreatic cancer: a satisfactory outcome in exchange for a lower resection rate. Surg Today. 2019;49(8):670–7.
doi: 10.1007/s00595-019-01776-y
pubmed: 30730003
Kimura Y, Nakamura T, Hayashi T, et al. Clinical usefulness of conversion surgery for unresectable pancreatic cancer diagnosed on multidetector computed tomography imaging: results from a multicenter observational cohort study by the Hokkaido Pancreatic Cancer Study Group (HOPS UR-01). Ann Gastroenterol Surg. 2019;3(5):523–33.
doi: 10.1002/ags3.12272
pubmed: 31549012
pmcid: 6749954
Gemenetzis G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270(2):340–7.
doi: 10.1097/SLA.0000000000002753
pubmed: 29596120
Byun Y, Han Y, Kang JS, et al. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. J Hepatobiliary Pancreat Sci. 2019;26(9):416–25.
doi: 10.1002/jhbp.648
pubmed: 31218836
Lee J, Lee JC, Gromski MA, et al. Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: a single center experience. Medicine (Baltimore). 2018;97(50):e13592.
doi: 10.1097/MD.0000000000013592
pubmed: 30558029
Blazer M, Wu C, Goldberg RM, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22(4):1153–9.
doi: 10.1245/s10434-014-4225-1
pubmed: 25358667
Opendro SS, Satoi S, Yanagimoto H, et al. Role of adjuvant surgery in initially unresectable pancreatic cancer after long-term chemotherapy or chemoradiation therapy: Survival benefit? J Hepatobiliary Pancreat Sci. 2014;21(9):695–702.
doi: 10.1002/jhbp.119
pubmed: 24841048
Satoi S, Yamaue H, Kato K, et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2013;20(6):590–600.
doi: 10.1007/s00534-013-0616-0
pubmed: 23660962
Kirkegård J, Mortensen FV, Cronin-Fenton D. Comment on “Surgery improves survival after neoadjuvant therapy for borderline and locally advanced pancreatic cancer.” Ann Surg. 2019;270(6):e138–9.
doi: 10.1097/SLA.0000000000003422
pubmed: 31356282
Lai TY, Hu YW. Neoadjuvant therapy in resectable pancreatic cancer: immortal time bias and its correction. J Clin Oncol. 2017;35(14):1623.
doi: 10.1200/JCO.2016.71.2273
pubmed: 28135147
Farnes I, Kleive D, Verbeke CS, et al. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2). BJS Open. 2023;7(6):zrad137.
doi: 10.1093/bjsopen/zrad137
pubmed: 38155512
pmcid: 10755199
Tempero MA, Malafa MP, Chiorean EG, et al. Pancreatic adenocarcinoma, version 1.2019. J Natl Compr Canc Netw. 2019;17(3):202–10.
doi: 10.6004/jnccn.2019.0014
pubmed: 30865919
Oba A, Ito H, Ono Y, et al. Regional pancreatoduodenectomy versus standard pancreatoduodenectomy with portal vein resection for pancreatic ductal adenocarcinoma with portal vein invasion. BJS Open. 2020;4(3):438–48.
doi: 10.1002/bjs5.50268
pubmed: 32191395
pmcid: 7260410
Inoue Y, Saiura A, Yoshioka R, et al. Pancreatoduodenectomy with systematic mesopancreas dissection using a supracolic anterior artery-first approach. Ann Surg. 2015;262(6):1092–101.
doi: 10.1097/SLA.0000000000001065
pubmed: 25587814
Inoue Y, Saiura A, Oba A, et al. Optimal extent of superior mesenteric artery dissection during pancreaticoduodenectomy for pancreatic cancer: balancing surgical and oncological safety. J Gastrointest Surg. 2019;23(7):1373–83.
doi: 10.1007/s11605-018-3995-3
pubmed: 30306451
Inoue Y, Saiura A, Sato T, et al. Details and outcomes of distal pancreatectomy with celiac axis resection preserving the left gastric arterial flow. Ann Surg Oncol. 2021;28(13):8283–94.
doi: 10.1245/s10434-021-10243-3
pubmed: 34143337
Sato T, Inoue Y, Takahashi Y, et al. Distal pancreatectomy with celiac axis resection combined with reconstruction of the left gastric artery. J Gastrointest Surg. 2017;21(5):910–7.
doi: 10.1007/s11605-017-3366-5
pubmed: 28116666
Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104(4):726–34.
doi: 10.1038/sj.bjc.6606087
pubmed: 21266974
pmcid: 3049591
Stotz M, Gerger A, Eisner F, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109(2):416–21.
doi: 10.1038/bjc.2013.332
pubmed: 23799847
pmcid: 3721392
Garcea G, Ladwa N, Neal CP, Metcalfe MS, Dennison AR, Berry DP. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg. 2011;35(4):868–72.
doi: 10.1007/s00268-011-0984-z
pubmed: 21312035
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
doi: 10.1097/01.sla.0000133083.54934.ae
pubmed: 15273542
pmcid: 1360123
Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127(11):1335–9.
doi: 10.1001/archsurg.1992.01420110083017
pubmed: 1359851
Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006;59(5):437–47.
doi: 10.1016/j.jclinepi.2005.07.004
pubmed: 16632131
Nowicka Z, Matyjek A, Płoszka K, Łaszczych M, Fendler W. Metanalyses on metformin’s role in pancreatic cancer suffer from severe bias and low data quality - An umbrella review. Pancreatology. 2023;23(2):192–200.
doi: 10.1016/j.pan.2023.01.007
pubmed: 36697348
Kato H, Horiguchi A, Ito M, Asano Y, Arakawa S. Essential updates 2019/2020: multimodal treatment of localized pancreatic adenocarcinoma: current topics and updates in survival outcomes and prognostic factors. Ann Gastroenterol Surg. 2021;5(2):132–51.
doi: 10.1002/ags3.12427
pubmed: 33860134
pmcid: 8034700
Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol. 2005;162(10):1016–23.
doi: 10.1093/aje/kwi307
pubmed: 16192344
Perri G, Prakash L, Qiao W, et al. Response and survival associated with first-line FOLFIRINOX vs gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma. JAMA Surg. 2020;155(9):832–9.
doi: 10.1001/jamasurg.2020.2286
pubmed: 32667641
pmcid: 7364337
Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 2008;26(24):3913–5.
doi: 10.1200/JCO.2008.16.1000
pubmed: 18711176
Omiya K, Maekawa A, Oba A, et al. A proposal of ABCD metastasectomy criteria for synchronous/metachronous metastatic pancreatic cancer in the era of multidisciplinary treatment. Br J Surg. 2024;111(1):znad417.
doi: 10.1093/bjs/znad417
pubmed: 38215237
Larsson P, Søreide K. Surgery for oligometastatic pancreatic cancer: next frontier? Br J Surg. 2024;111(1):znad419.
doi: 10.1093/bjs/znad419
pubmed: 38215238